Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 19/20 | 0.57 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12274188 | 0.89 | QPCT (0.59) | QPCTQPCTL | |
| SCHEMBL12456221 | 0.83 | QPCT (0.56) | QPCTQPCTL | |
| SCHEMBL12274345 | 0.82 | QPCT (0.62) | QPCTQPCTL | |
| SCHEMBL1444630 | 0.81 | QPCT (0.79) | QPCTQPCTL | |
| SCHEMBL29410496 | 0.81 | QPCT (0.85) | QPCTQPCTL | |
| SCHEMBL466518 | 0.81 | QPCT (0.85) | QPCTQPCTL | |
| SCHEMBL1713351 | 0.81 | QPCT (0.85) | QPCTQPCTL | |
| SCHEMBL466448 | 0.81 | QPCT (0.85) | QPCTQPCTL | |
| SCHEMBL12273961 | 0.81 | QPCT (0.56) | QPCTQPCTL | |
| SCHEMBL12274394 | 0.80 | QPCT (0.68) | QPCTQPCTLMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686313-B1 | BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2686313-A1 | BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8530670-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20120237475-A1 | Novel Inhibitors | PROBIODRUG AG (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123563-A1 | BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237475-A1 | Novel Inhibitors | GLS, NQO2, GLS2 | QPCT 5/4885QPCTL 13/4885MEN1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.